Literature DB >> 24398760

Levels of vascular endothelial growth factor and matrix metalloproteinase-9 proteins in patients with glioma.

Chengyuan Ma1, Yang Li, Xianfeng Zhang, Gang Zhao, Haiyang Xu.   

Abstract

OBJECTIVE: To investigate the levels of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) proteins in patients with glioma, in order to determine if either protein has prognostic value.
METHOD: The presence of VEGF and MMP-9 proteins in paraffin-embedded tumour specimens from patients with glioma was detected using immunohistochemistry. The correlation between the levels of VEGF and MMP-9 proteins and tumour grade was analysed.
RESULTS: A total of 32 patients with low-grade gliomas (World Health Organization [WHO] grade II) and 48 patients with high-grade gliomas (WHO grades III-IV) participated in the study. Positive immunohistochemical staining of VEGF and MMP-9 proteins was detected in 58/80 (72.5%) and 60/80 (75.0%) of patients, respectively. The level of VEGF immunostaining was significantly positively correlated with the level of MMP-9 immunostaining (r = 0.78). Significantly more high-grade gliomas (grades III-IV) demonstrated positive VEGF and MMP-9 immunostaining compared with the low grade gliomas (grades I-II).
CONCLUSIONS: These data suggest that VEGF and MMP-9 play an important role in the malignant behaviour of gliomas.

Entities:  

Keywords:  Glioma; MMP-9; VEGF; immunohistochemistry; matrix metalloproteinase-9; vascular endothelial growth factor

Mesh:

Substances:

Year:  2014        PMID: 24398760     DOI: 10.1177/0300060513481924

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

1.  High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas.

Authors:  Lei Wang; Luyao Zhang; Weigao Shen; Yanbo Liu; Yinan Luo
Journal:  Exp Ther Med       Date:  2015-12-02       Impact factor: 2.447

2.  Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.

Authors:  Wenjie Chen; Deshen He; Zuyun Li; Xin Zhang; Denghua Pan; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Creation of an apoptin-derived peptide that interacts with SH3 domains and inhibits glioma cell migration and invasion.

Authors:  Weiwei Song; Hengyu Zhao; Zhongqi Cui; Xiaoyu Ma; Wenwen Zhang; Di Wang; Anqi Liu; Lijie Yuan
Journal:  Tumour Biol       Date:  2016-09-29

4.  The Clinical Utility of Matrix Metalloproteinase 9 in Evaluating Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis.

Authors:  Xiangshan Yang; Shunzeng Lv; Yuting Liu; Daotang Li; Ranran Shi; Zhenyu Tang; Jianzhen Fan; Zhongfa Xu
Journal:  Mol Neurobiol       Date:  2014-08-10       Impact factor: 5.590

5.  Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.

Authors:  Song Xue; Man Hu; Peifeng Li; Ji Ma; Li Xie; Feifei Teng; Yufang Zhu; Bingjie Fan; Dianbin Mu; Jinming Yu
Journal:  Oncotarget       Date:  2017-07-25

Review 6.  Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets.

Authors:  Olivia G Taylor; Joshua S Brzozowski; Kathryn A Skelding
Journal:  Front Oncol       Date:  2019-09-26       Impact factor: 6.244

7.  A case report of targeted therapy with apatinib in a patient with recurrent high grade glioma.

Authors:  Xiuping Ding; Jujie Sun; Tingyong Fan; Baosheng Li
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.